4 - GELESIS HOLDINGS, INC. (0001805087) (Issuer)

25-NSE - GELESIS HOLDINGS, INC. (0001805087) (Subject)

8-K - CAPSTAR SPECIAL PURPOSE ACQUISITION CORP. (0001805087) (Filer)

425 - CAPSTAR SPECIAL PURPOSE ACQUISITION CORP. (0001805087) (Subject)

8-K - CAPSTAR SPECIAL PURPOSE ACQUISITION CORP. (0001805087) (Filer)

425 - CAPSTAR SPECIAL PURPOSE ACQUISITION CORP. (0001805087) (Subject)

425 - CAPSTAR SPECIAL PURPOSE ACQUISITION CORP. (0001805087) (Subject)

8-K - CAPSTAR SPECIAL PURPOSE ACQUISITION CORP. (0001805087) (Filer)

EFFECT - CAPSTAR SPECIAL PURPOSE ACQUISITION CORP. (0001805087) (Filer)

S-4/A - CAPSTAR SPECIAL PURPOSE ACQUISITION CORP. (0001805087) (Filer)

S-4/A - CAPSTAR SPECIAL PURPOSE ACQUISITION CORP. (0001805087) (Filer)

SC 13G - CAPSTAR SPECIAL PURPOSE ACQUISITION CORP. (0001805087) (Subject)

Strong capital base with PureTech Level Cash and Cash Equivalents of $341.4 million1 and Consolidated Cash and Cash Equivalents of $365.9 million2 as of June 30, 2022, excluding up to $115.4 million added post-period3; Operational runway extended into Q1 2026 Significant advancement of PureTech's Wholly Owned Programs, with three clinical trials underway, four completed, and human proof-of-principle achieved for a key PureTech platform Excellent progress across the Founded Entities, including Karuna's positive topline Phase 3 results for KarXT in schizophrenia, Akili's Nasdaq listing and Gelesis' commercial progress with Plenity®4 in the post-period, and four clinical data publications ac

Gelesis' six-month study of weight loss in adults with overweight or obesity who have prediabetes or type 2 diabetes met both of its primary endpoints: the proportion of participants who achieved at least 5% body weight loss (i.e., "Categorical") and the change in body weight after six months of therapy GS200 demonstrated a highly favorable Categorial weight loss response and tolerability in a population that often struggles to lose weight and is at high risk for obesity-related complications; the overall incidence of adverse events (AEs) in adults treated with GS200 was similar to the placebo group ~6 out of 10 GS200-treated adults achieved at least 5% weight loss ("Responders"), losing

New preclinical data presented today at the World of Microbiome Conference suggest adding superabsorbent hydrogel to a high-fat "western-like" diet prevents unfavorable changes in the communities of gut bacteria associated with diet-induced weight gain PureTech Health plc (NASDAQ:PRTC, LSE: PRTC))) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company announced that its Founded Entity, Gelesis Holdings, Inc. (NYSE:GLS) ("Gelesis), released today a poster prPesentation at the World of Microbiome annual meeting in Vienna. The preclinical study showed administration of one of Gelesis' proprietary superabsorbent hydrogels, Gel-B, significantly shifted the composition of the m

Strong capital base with PureTech level cash and cash equivalents of $418.9 million1 and consolidated cash and cash equivalents of $465.7 million2 as of December 31, 2021 Rapidly progressing pipeline of 27 therapeutics and therapeutic candidates, across Wholly Owned and Founded Entity programs, with 11 clinical trials initiated and 6 clinical trial readouts in 2021 Founded Entities continuing to mature and generate value for PureTech, with three now publicly traded and a fourth soon expected to go public Reviewing capital allocation strategy to drive additional value to shareholders with potential returns of capital through various mechanisms Company to host a webcast and conference cal

Proceeds from this transaction will be used to further support the national launch of Plenity Gelesis will begin trading on the New York Stock Exchange as "GLS" on Friday, January 14, 2022 and will ring the opening bell on Tuesday, January 18 PureTech Health plc (NASDAQ:PRTC, LSE: PRTC))) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company noted today that its Founded Entity, Gelesis, Inc. ("Gelesis"), the maker of Plenity®, an FDA-cleared weight management approach, announced the completion of its business combination with Capstar Special Purpose Acquisition Corp. (NYSE:CPSR) ("Capstar"). The publicly traded company will be known as Gelesis Holdings, Inc. and will beg

Proceeds from this transaction will be used to further support the national launch of Plenity Gelesis will begin trading on the New York Stock Exchange as "GLS" on Friday, January 14, 2022 and will ring the opening bell on Tuesday, January 18 Gelesis, the maker of Plenity®, an FDA-cleared weight management approach, announced today the completion of its business combination with Capstar Special Purpose Acquisition Corp. (NYSE:CPSR) ("Capstar"). The publicly traded company will be known as Gelesis Holdings, Inc. ("Gelesis" or "the Company") and will commence trading on the New York Stock Exchange under the ticker symbol "GLS" on January 14, 2022. Both Gelesis Inc. and Capstar shareholders

Ms. Bauerlein brings success in scaling to $300M+ revenue in direct-to-consumer business model and public company execution as Gelesis plans to scale Plenity® to meet growing consumer demand with its upcoming NYSE listing Registration Statement filed in connection with proposed business combination between Gelesis and Capstar declared effective by SEC PureTech Health plc (NASDAQ:PRTC, LSE: PRTC))) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, is pleased to note that its Founded Entity, Gelesis, announced the appointment of senior financial executive

Ms. Bauerlein brings success in scaling to $300M+ revenue in direct-to-consumer business model and public company execution as Gelesis plans to scale Plenity® to meet growing consumer demand with its upcoming NYSE listing Bauerlein joins Gelesis' board of industry veterans and luminaries who have deep expertise in direct-to-consumer brands, healthcare, and biotechnology Registration Statement filed in connection with proposed business combination between Gelesis and Capstar declared effective by SEC Gelesis, a biotherapeutics company focused on excess weight and metabolic disorders and the maker of Plenity®, announced the appointment of senior financial executive Ali Bauerlein to its Bo

With the prevalence of fad diets, food shaming and resulting guilt, leading health experts advise against villainizing specific food groups and moving to flexibility and moderation One-of-a-kind, multisensory activation from Plenity® highlights this shifting conversation, rejecting the idea that weight loss is synonymous with deprivation Gelesis, the maker of Plenity®, an FDA-cleared weight management approach, has created an edible billboard in New York City's Astor Place to challenge the idea that people can't eat the foods they love while losing weight. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211216005297/en/Plenity c

Plenity® is transforming weight management with a clinically proven approach made from naturally derived building blocks As Chief Nutrition Officer, Bauer will focus on educating healthcare professionals and offering nutrition counseling to Plenity members PureTech Health plc (NASDAQ:PRTC, LSE: PRTC))) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted today that its Founded Entity, Gelesis, Inc. ("Gelesis") announced that Plenity®, an FDA cleared weight management approach, is now broadly available across the United States to adults who meet the prescription criteria. Gelesis also announced the appointment of leading health and nutrition authority Joy Bauer, M